Amneal Pharmaceuticals, Inc. · NASDAQ:AMRX
Amneal Pharmaceuticals — 42nd Annual J.P. Morgan Healthcare Conference (January 2024)
20 slides from Amneal Pharmaceuticals's conference presentation, Jan 10, 2024
Slide 1: Amneal Pharmaceuticals
Amneal Pharmaceuticals Chirag Patel, Co-founder & Co-CEO Our mission is to be J.P. Morgan Healthcare Conference America’s #1 Affordable January 10, 2024 Medicines Company
Slide 2: Cautionary Statement on Forward Looking Statements
Cautionary Statement on Forward Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements reg
Slide 3: Today's agenda
Today’s agenda Discussion topics Q&A participants 1 Macro trends and large markets Growing demand and need for dependable supply 2 Amneal overview Diversified & growing global pharmaceutical company 3 Our growth strategy Key pillars of value creation Chirag Patel Tasos Konidaris Co-founder & Co-CEO
Slide 4: Macro trends are accelerating growth in essential medicines
1) Macro trends & large markets 2) Amneal overview 3) Our growth strategy Macro trends are accelerating growth in essential medicines Macro trend Amneal value proposition Global aging population using Growing portfolio of 270+ medicines across more daily medicines than ever Retail, Injectables, Bios
Slide 5: Strategy aligned with large & growing addressable markets
1) Macro trends & large markets 2) Amneal overview 3) Our growth strategy Strategy aligned with large & growing addressable markets Key U.S. pharmaceutical markets expected to grow to $100B+ by 2030 Retail Injectables Biosimilars Specialty (CNS & Endo) $29B $21B $44B $14B $25B $14B $17B $7B • Better
Slide 6: Amneal Pharmaceuticals – We make healthy possible
1) Macro trends & large markets 2) Amneal overview 3) Our growth strategy Amneal Pharmaceuticals – We make healthy possible® • Our goal is to be America’s #1 affordable medicines company • Global diversified pharmaceuticals company with a growing portfolio of 270+ commercial Amneal medicines across
Slide 7: Amneal today is a fundamentally stronger company
1) Macro trends & large markets 2) Amneal overview 3) Our growth strategy Amneal today is a fundamentally stronger company FY 2019 FY 2023(1) 1 Larger revenue base $1.6B ~$2.4B 2 Accelerating revenue growth (2%) +~8% Significantly more diversified 3 Oral solid generics % of total revenue 53% 26% Dee
Slide 8: Track record of driving top and bottom-line growth
1) Macro trends & large markets 2) Amneal overview 3) Our growth strategy Track record of driving top and bottom-line growth Net Revenue Growth Adjusted EBITDA(2) Growth High single- ($ millions) ($ millions) digit growth $2,370 – $2,420 +22.5% +5.7% $2,212 High-single $540 – $550 +5.1% $2,094 (+4.5
Slide 9: Affordable medicines portfolio driving sustainable growth
1) Macro trends & large markets 2) Amneal overview 3) Our growth strategy Affordable medicines portfolio driving sustainable growth • Diverse portfolio of 230+ retail products shifting +4% net revenue CAGR 2020 – Q3 2023 towards complex and high-value medicines Retail ($ millions) • Ability to devel
Slide 10: Growing and expanding Specialty branded business
1) Macro trends & large markets 2) Amneal overview 3) Our growth strategy Growing and expanding Specialty branded business Specialty highlights Expect $500M+ sales by 2027 Expected specialty launches(1) ($ millions) Potential Therapeutic • Therapeutic focus on Neurology $500+ Program Launch Area and
Slide 11: Ongoing double-digit growth in AvKARE distribution business
1) Macro trends & large markets 2) Amneal overview 3) Our growth strategy Ongoing double-digit growth in AvKARE distribution business 15%+ revenue CAGR expected from 2020 to 2025 AvKARE strategic focus areas ($ millions) $600+ • Operates as a contract administrator (wholesaler ~$500 and re-packager
Slide 12: Clear strategy and outlook for sustainable growth across portfolio
1) Macro trends & large markets 2) Amneal overview 3) Our growth strategy Clear strategy and outlook for sustainable growth across portfolio Net Revenue Business area Strategy for growth Growth projection(1) 2023E Grow #4 U.S. Retail portfolio of 230+ products with new launches Retail Low single-dig
Slide 13: Highlighting key near-term catalysts
1) Macro trends & large markets 2) Amneal overview 3) Our growth strategy Highlighting key near-term catalysts Naloxone HCl Retail & Injectables ALYMSYS® IPX203 Nasal Spray New Product Launches Product type Biosimilar Complex generics Specialty Generics portfolio Therapeutic area Oncology Anti-overd
Slide 14: Recent and upcoming growth catalysts across portfolio
1) Macro trends & large markets 2) Amneal overview 3) Our growth strategy Recent and upcoming growth catalysts across portfolio Retail Injectables Biosimilars Specialty International Recently 2023 launches 2023 Launches Launched IPX203 pending NDA Launched achieved ✓ Posaconazole, Pirfenidone, Lubip
Slide 15: Executing on Amneal's four pillars of value creation
1) Macro trends & large markets 2) Amneal overview 3) Our growth strategy Executing on Amneal’s four pillars of value creation (2) (3) Key Pillar Metric 2019 2023E Growth projection Increased #1 OSD(1) Gx % of revenue 53% 26% <20% by 2027 diversification Revenues $1.6B ~$2.4B High single-digit growt
Slide 16: Appendix
amneal We make healthy possible Appendix
Slide 17: Driving innovations to deliver best-in-class affordable medicines
Driving innovations to deliver best-in-class affordable medicines DHE (Migraine & Cluster Headache) acquisition FyInetra® (pegfilgrastim) Acquires InterPharm K-130 Alymsys® (Symptomatic New York Injectables India (bevacizumab) neurogenic Amneal founded orthostatic Transdermal Releuko® hypotension) N
Slide 18: Differentiated R&D and manufacturing capabilities
Differentiated R&D and manufacturing capabilities Best-in-class R&D and manufacturing capabilities Global network of FDA-approved, delivering complex & high-value dosage forms cGMP manufacturing sites INJECTABLES TRANSDERMALS ORAL SOLIDS, & STERILE LIQUIDS & TOPICALS Matrix Peptides Hydrogel IR/ER t
Slide 19: Entering key global markets with impactful pharmaceuticals
INTERNATIONAL EXPANSION Entering key global markets with impactful pharmaceuticals Geography Direct / Partner Strategy and status India Direct • Utilizing commercial team to launch Expanding local products locally presence • Focusing on the hospital, ophthalmics, and specialty products markets Europ
Slide 20: Reconciliation of net (loss) income to EBITDA & adjusted EBITDA
Reconciliation of net (loss) income to EBITDA & adjusted EBITDA Note: Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures. 20
Amneal Pharmaceuticals — 42nd Annual J.P. Morgan Healthcare Conference (January 2024) on 6ix